<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02725710</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00063872</org_study_id>
    <nct_id>NCT02725710</nct_id>
  </id_info>
  <brief_title>Gabapentin as an Adjunct to Perioperative Pain Management Regimens for Uterine Aspiration</brief_title>
  <acronym>GABA</acronym>
  <official_title>Gabapentin as an Adjunct to Perioperative Pain Management Regimens for Uterine Aspiration: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled double-blind placebo-controlled trial evaluating the impact
      of gabapentin given preoperatively on perioperative pain scores for women receiving uterine
      aspiration between 6 and 14+6 weeks gestation. This study will be a trial included in a
      prospective meta-analysis evaluating the use of gabapentin on perioperative pain in the
      abortion setting.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Actual">June 14, 2018</completion_date>
  <primary_completion_date type="Actual">June 13, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Score on 100-mm VAS (Visual Analog Scale) at 5 Minutes Post-procedure</measure>
    <time_frame>5 minutes</time_frame>
    <description>Score range of 0 to 100, where 0 means no pain and 100 means worst pain in my life.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Score on the 100-mm VAS</measure>
    <time_frame>Baseline (pre-operatively immediately prior to the procedure), 10 minutes, 30 minute</time_frame>
    <description>Measured at baseline, 10 minutes post-procedure, and 30 minutes post-procedure. Score range of 0 to 100, where 0 means no pain and 100 means worst pain in my life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative Nausea as Measured by 100-mm VAS</measure>
    <time_frame>Baseline (pre-operatively immediately prior to the procedure), 10 minutes, 30 minutes</time_frame>
    <description>Score range of 0 to 100, where 0 means no nausea and 100 means worst nausea in my life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Experiencing Perioperative Vomiting</measure>
    <time_frame>Baseline (pre-operatively immediately prior to the procedure), 10 minutes, 30 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative Anxiety as Measured by the 100-mm VAS</measure>
    <time_frame>5 minutes, 10 minutes, 30 minutes, discharge</time_frame>
    <description>Score range of 0 to 100, where 0 means no anxiety and 100 means extremely anxious.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Using Pain Medications</measure>
    <time_frame>24 hours post-operatively</time_frame>
    <description>Pain medications included ibuprofen and oxycodone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Experiencing Side Effects</measure>
    <time_frame>10 minutes post-procedure</time_frame>
    <description>Side effects noted are dizziness, ataxia, somnolence, asthenia, headache, and amblyopia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain (on a 5-point Scale)</measure>
    <time_frame>Post-operative day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea (on a 5-point Scale)</measure>
    <time_frame>Post-operative day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vomiting (on a 5-point Scale)</measure>
    <time_frame>Post-operative day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effects (on a 5-point Scale)</measure>
    <time_frame>Post-operative day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General Satisfaction With the Procedure (on a 5-point Scale)</measure>
    <time_frame>Post-operative day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Other Abortion</condition>
  <condition>Spontaneous Abortion</condition>
  <arm_group>
    <arm_group_label>Group 1: Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Usual perioperative pain management protocol PLUS placebo orally 1-2 hour prior to procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Gabapentin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Usual perioperative pain management protocol PLUS 600mg Gabapentin administered orally 1-2 hour prior to procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>600mg Gabapentin administered orally 1-2 hours prior to procedure</description>
    <arm_group_label>Group 2: Gabapentin</arm_group_label>
    <other_name>Neurontin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Identical looking pill to the 600mg Gabapentin pill administered orally 1-2 hours prior to procedure</description>
    <arm_group_label>Group 1: Placebo</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women &gt;=18 years-old

          -  Presenting for a surgical abortion

          -  No contraindication to outpatient abortion

          -  No contraindication to gabapentin

          -  Fluency in English and able to provide informed consent

        Exclusion Criteria:

          -  Allergy, sensitivity or contraindication to gabapentin

          -  Severe renal disease

          -  Currently using gabapentin or pregalabin
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beverly Gray, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>March 2, 2016</study_first_submitted>
  <study_first_submitted_qc>March 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2016</study_first_posted>
  <results_first_submitted>June 12, 2019</results_first_submitted>
  <results_first_submitted_qc>June 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 2, 2019</results_first_posted>
  <last_update_submitted>June 12, 2019</last_update_submitted>
  <last_update_submitted_qc>June 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>uterine aspiration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abortion, Spontaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 16, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT02725710/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruited between August 2016 and June 2018.</recruitment_details>
      <pre_assignment_details>One subject randomized to gabapentin withdrew from the procedure.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1: Placebo</title>
          <description>Usual perioperative pain management protocol PLUS placebo orally 1-2 hour prior to procedure.
Placebo: Identical looking pill to the 600mg Gabapentin pill administered orally 1-2 hours prior to procedure</description>
        </group>
        <group group_id="P2">
          <title>Group 2: Gabapentin</title>
          <description>Usual perioperative pain management protocol PLUS 600mg Gabapentin administered orally 1-2 hour prior to procedure.
Gabapentin: 600mg Gabapentin administered orally 1-2 hours prior to procedure</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1: Placebo</title>
          <description>Usual perioperative pain management protocol PLUS placebo orally 1-2 hour prior to procedure.
Placebo: Identical looking pill to the 600mg Gabapentin pill administered orally 1-2 hours prior to procedure</description>
        </group>
        <group group_id="B2">
          <title>Group 2: Gabapentin</title>
          <description>Usual perioperative pain management protocol PLUS 600mg Gabapentin administered orally 1-2 hour prior to procedure.
Gabapentin: 600mg Gabapentin administered orally 1-2 hours prior to procedure</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="48"/>
            <count group_id="B2" value="47"/>
            <count group_id="B3" value="95"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.8" spread="6.3"/>
                    <measurement group_id="B2" value="31.7" spread="6.1"/>
                    <measurement group_id="B3" value="31.7" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Pain</title>
          <description>Measured using the 100-mm visual analog scale (VAS), where 0 means no pain and 100 means worst pain in my life.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.3" lower_limit="0.5" upper_limit="22.3"/>
                    <measurement group_id="B2" value="3.0" lower_limit="0.0" upper_limit="9.0"/>
                    <measurement group_id="B3" value="3.0" lower_limit="0.0" upper_limit="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Score on 100-mm VAS (Visual Analog Scale) at 5 Minutes Post-procedure</title>
        <description>Score range of 0 to 100, where 0 means no pain and 100 means worst pain in my life.</description>
        <time_frame>5 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Placebo</title>
            <description>Usual perioperative pain management protocol PLUS placebo orally 1-2 hour prior to procedure.
Placebo: Identical looking pill to the 600mg Gabapentin pill administered orally 1-2 hours prior to procedure</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Gabapentin</title>
            <description>Usual perioperative pain management protocol PLUS 600mg Gabapentin administered orally 1-2 hour prior to procedure.
Gabapentin: 600mg Gabapentin administered orally 1-2 hours prior to procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Score on 100-mm VAS (Visual Analog Scale) at 5 Minutes Post-procedure</title>
          <description>Score range of 0 to 100, where 0 means no pain and 100 means worst pain in my life.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.7" spread="27.5"/>
                    <measurement group_id="O2" value="37.1" spread="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.56</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Score on the 100-mm VAS</title>
        <description>Measured at baseline, 10 minutes post-procedure, and 30 minutes post-procedure. Score range of 0 to 100, where 0 means no pain and 100 means worst pain in my life.</description>
        <time_frame>Baseline (pre-operatively immediately prior to the procedure), 10 minutes, 30 minute</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Placebo</title>
            <description>Usual perioperative pain management protocol PLUS placebo orally 1-2 hour prior to procedure.
Placebo: Identical looking pill to the 600mg Gabapentin pill administered orally 1-2 hours prior to procedure</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Gabapentin</title>
            <description>Usual perioperative pain management protocol PLUS 600mg Gabapentin administered orally 1-2 hour prior to procedure.
Gabapentin: 600mg Gabapentin administered orally 1-2 hours prior to procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Score on the 100-mm VAS</title>
          <description>Measured at baseline, 10 minutes post-procedure, and 30 minutes post-procedure. Score range of 0 to 100, where 0 means no pain and 100 means worst pain in my life.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="0.5" upper_limit="22.3"/>
                    <measurement group_id="O2" value="3.0" lower_limit="0.0" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.8" lower_limit="7.5" upper_limit="42.5"/>
                    <measurement group_id="O2" value="20.0" lower_limit="3.0" upper_limit="47.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6" lower_limit="3.3" upper_limit="30.8"/>
                    <measurement group_id="O2" value="9.5" lower_limit="1.0" upper_limit="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Perioperative Nausea as Measured by 100-mm VAS</title>
        <description>Score range of 0 to 100, where 0 means no nausea and 100 means worst nausea in my life.</description>
        <time_frame>Baseline (pre-operatively immediately prior to the procedure), 10 minutes, 30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Placebo</title>
            <description>Usual perioperative pain management protocol PLUS placebo orally 1-2 hour prior to procedure.
Placebo: Identical looking pill to the 600mg Gabapentin pill administered orally 1-2 hours prior to procedure</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Gabapentin</title>
            <description>Usual perioperative pain management protocol PLUS 600mg Gabapentin administered orally 1-2 hour prior to procedure.
Gabapentin: 600mg Gabapentin administered orally 1-2 hours prior to procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Perioperative Nausea as Measured by 100-mm VAS</title>
          <description>Score range of 0 to 100, where 0 means no nausea and 100 means worst nausea in my life.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="0.0" upper_limit="12.5"/>
                    <measurement group_id="O2" value="3.0" lower_limit="0.0" upper_limit="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="0.0" upper_limit="14.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.0" upper_limit="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="0.0" upper_limit="10.8"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.0" upper_limit="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Experiencing Perioperative Vomiting</title>
        <time_frame>Baseline (pre-operatively immediately prior to the procedure), 10 minutes, 30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Placebo</title>
            <description>Usual perioperative pain management protocol PLUS placebo orally 1-2 hour prior to procedure.
Placebo: Identical looking pill to the 600mg Gabapentin pill administered orally 1-2 hours prior to procedure</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Gabapentin</title>
            <description>Usual perioperative pain management protocol PLUS 600mg Gabapentin administered orally 1-2 hour prior to procedure.
Gabapentin: 600mg Gabapentin administered orally 1-2 hours prior to procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Experiencing Perioperative Vomiting</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Perioperative Anxiety as Measured by the 100-mm VAS</title>
        <description>Score range of 0 to 100, where 0 means no anxiety and 100 means extremely anxious.</description>
        <time_frame>5 minutes, 10 minutes, 30 minutes, discharge</time_frame>
        <population>One subject in the placebo group did not have anxiety at discharge measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Placebo</title>
            <description>Usual perioperative pain management protocol PLUS placebo orally 1-2 hour prior to procedure.
Placebo: Identical looking pill to the 600mg Gabapentin pill administered orally 1-2 hours prior to procedure</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Gabapentin</title>
            <description>Usual perioperative pain management protocol PLUS 600mg Gabapentin administered orally 1-2 hour prior to procedure.
Gabapentin: 600mg Gabapentin administered orally 1-2 hours prior to procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Perioperative Anxiety as Measured by the 100-mm VAS</title>
          <description>Score range of 0 to 100, where 0 means no anxiety and 100 means extremely anxious.</description>
          <population>One subject in the placebo group did not have anxiety at discharge measured.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5" lower_limit="10.0" upper_limit="50.5"/>
                    <measurement group_id="O2" value="23.5" lower_limit="6.0" upper_limit="49.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" lower_limit="3.8" upper_limit="43.5"/>
                    <measurement group_id="O2" value="11.0" lower_limit="4.0" upper_limit="36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" lower_limit="2.8" upper_limit="25.0"/>
                    <measurement group_id="O2" value="7.0" lower_limit="2.5" upper_limit="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" lower_limit="2.0" upper_limit="27.0"/>
                    <measurement group_id="O2" value="8.0" lower_limit="3.0" upper_limit="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Using Pain Medications</title>
        <description>Pain medications included ibuprofen and oxycodone.</description>
        <time_frame>24 hours post-operatively</time_frame>
        <population>The number of subjects analyzed for &quot;ibuprofen and oxycodone&quot; and &quot;oxycodone only&quot; reflects the number of subjects that received a prescription for opiates.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Placebo</title>
            <description>Usual perioperative pain management protocol PLUS placebo orally 1-2 hour prior to procedure.
Placebo: Identical looking pill to the 600mg Gabapentin pill administered orally 1-2 hours prior to procedure</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Gabapentin</title>
            <description>Usual perioperative pain management protocol PLUS 600mg Gabapentin administered orally 1-2 hour prior to procedure.
Gabapentin: 600mg Gabapentin administered orally 1-2 hours prior to procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Using Pain Medications</title>
          <description>Pain medications included ibuprofen and oxycodone.</description>
          <population>The number of subjects analyzed for &quot;ibuprofen and oxycodone&quot; and &quot;oxycodone only&quot; reflects the number of subjects that received a prescription for opiates.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No pain medication</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ibuprofen only</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ibuprofen and oxycodone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oxycodone only</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Experiencing Side Effects</title>
        <description>Side effects noted are dizziness, ataxia, somnolence, asthenia, headache, and amblyopia.</description>
        <time_frame>10 minutes post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Placebo</title>
            <description>Usual perioperative pain management protocol PLUS placebo orally 1-2 hour prior to procedure.
Placebo: Identical looking pill to the 600mg Gabapentin pill administered orally 1-2 hours prior to procedure</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Gabapentin</title>
            <description>Usual perioperative pain management protocol PLUS 600mg Gabapentin administered orally 1-2 hour prior to procedure.
Gabapentin: 600mg Gabapentin administered orally 1-2 hours prior to procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Experiencing Side Effects</title>
          <description>Side effects noted are dizziness, ataxia, somnolence, asthenia, headache, and amblyopia.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dizziness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ataxia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somnolence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asthenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amblyopia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain (on a 5-point Scale)</title>
        <time_frame>Post-operative day 1</time_frame>
        <population>Data not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Placebo</title>
            <description>Usual perioperative pain management protocol PLUS placebo orally 1-2 hour prior to procedure.
Placebo: Identical looking pill to the 600mg Gabapentin pill administered orally 1-2 hours prior to procedure</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Gabapentin</title>
            <description>Usual perioperative pain management protocol PLUS 600mg Gabapentin administered orally 1-2 hour prior to procedure.
Gabapentin: 600mg Gabapentin administered orally 1-2 hours prior to procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Pain (on a 5-point Scale)</title>
          <population>Data not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nausea (on a 5-point Scale)</title>
        <time_frame>Post-operative day 1</time_frame>
        <population>Data not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Placebo</title>
            <description>Usual perioperative pain management protocol PLUS placebo orally 1-2 hour prior to procedure.
Placebo: Identical looking pill to the 600mg Gabapentin pill administered orally 1-2 hours prior to procedure</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Gabapentin</title>
            <description>Usual perioperative pain management protocol PLUS 600mg Gabapentin administered orally 1-2 hour prior to procedure.
Gabapentin: 600mg Gabapentin administered orally 1-2 hours prior to procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Nausea (on a 5-point Scale)</title>
          <population>Data not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vomiting (on a 5-point Scale)</title>
        <time_frame>Post-operative day 1</time_frame>
        <population>Data not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Placebo</title>
            <description>Usual perioperative pain management protocol PLUS placebo orally 1-2 hour prior to procedure.
Placebo: Identical looking pill to the 600mg Gabapentin pill administered orally 1-2 hours prior to procedure</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Gabapentin</title>
            <description>Usual perioperative pain management protocol PLUS 600mg Gabapentin administered orally 1-2 hour prior to procedure.
Gabapentin: 600mg Gabapentin administered orally 1-2 hours prior to procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Vomiting (on a 5-point Scale)</title>
          <population>Data not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effects (on a 5-point Scale)</title>
        <time_frame>Post-operative day 1</time_frame>
        <population>Data not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Placebo</title>
            <description>Usual perioperative pain management protocol PLUS placebo orally 1-2 hour prior to procedure.
Placebo: Identical looking pill to the 600mg Gabapentin pill administered orally 1-2 hours prior to procedure</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Gabapentin</title>
            <description>Usual perioperative pain management protocol PLUS 600mg Gabapentin administered orally 1-2 hour prior to procedure.
Gabapentin: 600mg Gabapentin administered orally 1-2 hours prior to procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effects (on a 5-point Scale)</title>
          <population>Data not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>General Satisfaction With the Procedure (on a 5-point Scale)</title>
        <time_frame>Post-operative day 1</time_frame>
        <population>Data not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Placebo</title>
            <description>Usual perioperative pain management protocol PLUS placebo orally 1-2 hour prior to procedure.
Placebo: Identical looking pill to the 600mg Gabapentin pill administered orally 1-2 hours prior to procedure</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Gabapentin</title>
            <description>Usual perioperative pain management protocol PLUS 600mg Gabapentin administered orally 1-2 hour prior to procedure.
Gabapentin: 600mg Gabapentin administered orally 1-2 hours prior to procedure</description>
          </group>
        </group_list>
        <measure>
          <title>General Satisfaction With the Procedure (on a 5-point Scale)</title>
          <population>Data not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 minutes post-procedure</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1: Placebo</title>
          <description>Usual perioperative pain management protocol PLUS placebo orally 1-2 hour prior to procedure.
Placebo: Identical looking pill to the 600mg Gabapentin pill administered orally 1-2 hours prior to procedure</description>
        </group>
        <group group_id="E2">
          <title>Group 2: Gabapentin</title>
          <description>Usual perioperative pain management protocol PLUS 600mg Gabapentin administered orally 1-2 hour prior to procedure.
Gabapentin: 600mg Gabapentin administered orally 1-2 hours prior to procedure</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Amblyopia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jeremy M. Weber</name_or_title>
      <organization>Duke University</organization>
      <phone>919-681-4561</phone>
      <email>jeremy.m.weber@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

